Results 231 to 240 of about 354,322 (345)

A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma

Haematologica, 2014
Neha Korde, Mattias Carlsten, Min-Jung Lee, Alex Minter, Esther Tan, Mary Kwok, Elisabet Manasanch, Manisha Bhutani, Nishant Tageja, Mark Roschewski, Adriana Zingone, Rene Costello, Marcia Mulquin, Diamond Zuchlinski, Irina Maric, Katherine R. Calvo, Raul Braylan, Prashant Tembhare, Constance Yuan, Maryalice Stetler-Stevenson, Jane Trepel, Richard Childs, Ola Landgren   +22 more
doaj   +1 more source

Immunoparesis in multiple myeloma: a current overview. [PDF]

Front Oncol
Wang H, Chen J.
europepmc   +1 more source

Real-world drug regimes for multiple myeloma in a Swiss population (2012 to 2017) : cost-outcome description [PDF]

, 2019
Blozik, Eva, Eichler, Klaus, Rapold, Ronald, Reich, Oliver, Wieser, Simon   +4 more
core   +1 more source

Plasmablastic multiple myeloma with Dutcher bodies

, 2008
Deepali Jain, Tejinder Singh
openalex   +1 more source

An intracellular recombinant single‐chain variable antibody fragment as a new class of phosphodiesterase type 5 inhibitors

British Journal of Pharmacology, EarlyView.
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger involved in human (patho‐)physiology. Phosphodiesterase 5 (PDE5) is a major cGMP hydrolyzing enzyme in many cell types including vascular smooth muscle cells (VSMCs). Several highly selective PDE5 inhibitors are in clinical use. However, there are currently no
Kürsat Kirkgöz, Sophie Sprenger, Olga Schweigert, Sanika Mohagaonkar, Matti Walsdorff, Tanja Zeller, Filip Berisha, Viacheslav O. Nikolaev, Sergei D. Rybalkin   +8 more
wiley   +1 more source

PF611 MULTIPLE DRUG COMBINATIONS FOR FIRST‐LINE TREATMENT IN TRANSPLANT‐INELIGIBLE MULTIPLE MYELOMA PATIENTS: A SYSTEMATIC REVIEW AND NETWORK META‐ANALYSIS

, 2019
Vanessa Piechotta, Benjamin Scheckel, Peter Langer, Ina Monsef, Christof Scheid, Lise J Estcourt, Anne Adams, Kathrin Kuhr, Nicole Skoetz   +8 more
openalex   +1 more source

Protectin D1 and maresin 1 attenuate airway hyperreactivity induced by IL‐13 in human isolated small bronchi

British Journal of Pharmacology, EarlyView.
Background and Purpose Interleukin (IL)‐13 is implicated in airway hyperreactivity (AHR), a key feature of asthma. We explored the potential anti‐AHR activity of selected specialised pro‐resolving mediators (SPMs) in IL‐13‐induced AHR models, using human bronchial smooth muscle cells (BSMCs) and human isolated bronchi.
Willem Abma, Sven‐Erik Dahlén, Craig E. Wheelock, Mikael Adner, Mamdoh Al‐Amerie, Erik Sachs, Kasra Vali Jalali, Leonardo De Maria, Henric Olsson, Jesper Säfholm   +9 more
wiley   +1 more source

Clinical outcomes of lenalidomide, bortezomib, and dexamethasone in multiple myeloma patients. [PDF]

Am J Transl Res
Yu L, Ren L, Hou Z, Yang Y, Zhang K.
europepmc   +1 more source

PSMD12 Overexpression Promotes Lung Adenocarcinoma Progression via Ubiquitin–Proteasome Pathway Dysregulation

Cancer Science, EarlyView.
PSMD12, located on the frequently amplified 17q region in LUAD, is upregulated in tumors and associated with poor prognosis and advanced stage. Functional studies revealed that PSMD12 promotes cell proliferation and G2/M transition by inhibiting CDK1 ubiquitination and stabilizing CDK1.
Yuya Ono, Hajime Otsu, Takaaki Masuda, Keisuke Kosai, Shohei Shibuta, Kosuke Hirose, Takashi Ofuchi, Yuki Ando, Koto Kawata, Yasuo Tsuda, Yusuke Yonemura, Taro Tobo, Tomoyoshi Takenaka, Tomoharu Yoshizumi, Koshi Mimori   +14 more
wiley   +1 more source

Regulation of stress tolerance by CREB1 sustains multiple myeloma cell survival. [PDF]

Cell Death Dis
Kudalkar R, Altom J, Galloway J, Manning V, Taranto S, Cottini F.   +5 more
europepmc   +1 more source